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Abstract: The homeostatic control of lipid metabolism is essential for many fundamental physiological
processes. A deep understanding of its regulatory mechanisms is pivotal to unravel prospective
physiopathological factors and to identify novel molecular targets that could be employed to design
promising therapies in the management of lipid disorders. Here, we investigated the role of
bromodomain and extraterminal domain (BET) proteins in the regulation of lipid metabolism. To
reach this aim, we used a loss-of-function approach by treating HepG2 cells with JQ1, a powerful
and selective BET inhibitor. The main results demonstrated that BET inhibition by JQ1 efficiently
decreases intracellular lipid content, determining a significant modulation of proteins involved in lipid
biosynthesis, uptake and intracellular trafficking. Importantly, the capability of BET inhibition to slow
down cell proliferation is dependent on the modulation of cholesterol metabolism. Taken together,
these data highlight a novel epigenetic mechanism involved in the regulation of lipid homeostasis.
Keywords: BET proteins; cell proliferation; cholesterol; epigenetics; HMGCR; JQ1; LDLr; lipid
metabolism; SREBP; TMEM97
1. Introduction
The homeostatic regulation of lipid metabolism is essential for the maintenance of key cellular
processes involved in a plethora of biological functions. Fatty acids constitute the major energy source
and are fundamental constituents of cell membranes [1]. In addition, they serve as substrates for
cellular phospholipases, which convert these compounds into pivotal signalling factors implicated
in anti- and pro-inflammatory actions [2]. Similarly, cholesterol exerts both structural and functional
roles, being the precursor of steroid hormones, vitamin D and bile acids, and regulating the assembly
of specialized membrane microdomains called lipid rafts and caveolae [3].
During last decades, it has become increasingly clear that lipid homeostasis is crucial for cell
growth and proliferation [4,5], as membrane biosynthesis requires the coordinated assembly of different
lipid species during cell division, involving the concerted regulation of lipid biosynthesis, uptake,
subcellular localization and turnover [6]. For these reasons, the body employs an intricate homeostatic
network to regulate the availability of lipids for cells and tissues. This network mainly operates in
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the liver, where the major part of lipid metabolism takes place [3]. Hepatic cells are the principal site
for lipid biosynthesis, determined by the establishment of a complex series of enzymatic reactions;
in particular, 3-hydroxy-3-methylglutaryl Coenzyme A reductase (HMGCR) and Acyl Coenzyme
A carboxylase (ACC) represent the key and rate-limiting enzymes for cholesterol and fatty acid
synthesis, respectively [7,8]. Considering their central role in lipid biosynthesis, both HMGCR and
ACC are tightly regulated at both short- and long-term levels. Short-term regulation is controlled by
phosphorylative events, which negatively affect the activation state of the enzymes [9]. Conversely,
the long-term transcriptional regulation of the protein machinery involved in lipid metabolism is
mediated by sterol regulatory element binding proteins (SREBPs). When intracellular sterol content
is reduced, SREBPs precursors are proteolytically processed to form the NH(2)-terminal fragment
that enters the nucleus (nuclear, nSREBP) and induces the transcription of genes coding for lipogenic
enzymes, such as HMGCR and ACC [9,10]. Notably, SREBPs also promote the extracellular uptake of
lipoprotein-derived lipids by eliciting the transcription of lipoprotein receptors, such as low density
lipoprotein receptor (LDLr) and scavenger receptor class B type 1 (SR-B1) [11,12].
Lipid abnormalities play a crucial role in a plethora of pathological conditions, such as
cardiovascular diseases, neurodevelopmental alterations, neurodegenerative and lipid storage
disorders [13–15]. Despite the widespread use of lipid-lowering medications, effective pharmacological
approaches are still lacking for several lipid metabolism-related disorders. Thus, there is still a need to
better dissect the regulatory mechanisms of lipid homeostasis in order to identify novel molecular
targets that could be useful for designing promising therapeutic treatments.
Bromodomain and extra-terminal domain (BET) proteins, comprising BRD2, BRD3 and BRD4,
are epigenetic readers recruited to the chromatin by the presence of acetylated histones, thereby
regulating gene expression [16]. The involvement of these epigenetic sensors has been extensively
characterized in cancer and inflammation, because of their incontrovertible role in the transcriptional
modulation of oncogenes and mediators of the immune response [17,18]. BET proteins attracted
considerable interest in biomedical research, as they are extremely druggable by potent and specific
inhibitors. In this context, BET inhibition exerts anti-proliferative activity in different cancer
cells and shows outstanding anti-inflammatory properties in a number of physiopathological
conditions [17,19,20]. Recently, experimental evidence also demonstrated that the activity of BET
proteins may be extended to the regulation of metabolic processes. For instance, BET inhibition
strongly affects protein homeostasis, autophagy induction, reactive oxygen species (ROS) and glucose
metabolism [17,21–24]. Conversely, the prospective role exerted by BET proteins on lipid metabolism
is still poorly characterized. Microarray analysis suggested that the BET inhibitor RVX-208 induces
changes in ApoA1 and high density lipoprotein (HDL) levels [25]. Coherently, overexpression of BET
proteins increased cholesterol biosynthesis [26]. Furthermore, it has been observed that BET inhibition
efficiently counteracted plasma low density lipoprotein (LDL) alterations in a mouse model of cancer
cachexia [17]. Despite this evidence, no studies systematically addressed the involvement of BET
proteins in the modulation of the main proteins and enzymes controlling the regulatory machinery
of lipid metabolism. A better comprehension of these mechanisms is essential to identify novel
physiological regulatory pathways and to select innovative therapeutic targets. Here, we provide a
proof of concept study, aimed at evaluating the putative role of BET modulation on lipid homeostasis.
To reach this objective, we took advantage of a loss-of-function approach by using JQ1 as a potent
and specific inhibitor of BET protein activity [27]. The effects induced by BET inhibition were mainly
evaluated in HepG2 cell line, a human liver-derived cell culture model widely used to assess lipid
homeostasis [28–30].
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2. Results
2.1. BET Inhibition Decreases Lipid Content in HepG2 Cells
In order to evaluate the putative involvement of BET inhibition on lipid homeostasis, the effect
of JQ1 on cellular lipid content was firstly assessed. HepG2 cells were treated with JQ1 for 48 hours,
and Oil Red O staining was employed as a widely used and accurate method to measure neutral
lipids [31]. Descriptive evaluation highlighted that the number of lipid droplets, as well as their size,
appeared reduced in JQ1-treated cells (Figure 1A). This result corroborated the quantitative assessment
of lipid content estimated by Oil Red O absorbance, which showed a significant five-fold decrease
upon BET inhibition (Figure 1B). Coherently, immunofluorescence intensity of the lipid droplet marker
perilipin-2 (Plin2) was found to be lower 48 hours after pharmacological BET blockade (Figure 1C).
Notably, JQ1 was also effective in reducing the amount of intracellular cholesterol, as observable by
filipin staining and quantification (Figure 1D). Thus, BET inhibition significantly lowers lipid content
in HepG2 cells.
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quantified by spectrophotometry to evaluate the amount of neutral lipids. n = 6 different experiments. 
(C) Vehicle- and JQ1-treated HepG2 cells were fixed and stained with antibody against Plin2 (red). 
DAPI was used as a nuclear counterstain. Scale bar: 25 µm (D) Representative image (left panel) and 
quantification of the mean fluorescence intensity (right panel) of filipin staining performed on HepG2 
cells treated with vehicle and JQ1 for 48 hours. n = 5 different experiments. Scale bar: 50 µm. Data 
represent means ± SD. Statistical analysis was performed by using unpaired Student’s t test. ** p < 
0.01; *** p < 0.001. 
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cells (Figure 2A). However, no changes were observed in the ratio between the phosphorylated 
fraction of ACC and its total levels, suggesting that BET inhibition modulated the protein amount of 
the enzyme without influencing its activation state by inhibitory phosphorylation. Similar results 
were obtained by analyzing HMGCR; in fact, JQ1 administration strongly reduced the protein levels 
of the enzyme without affecting its phosphorylation state (Figure 2B). The effect of BET inhibition on 
Figure 1. Effects of bromodomain and extraterminal domain (BET) inhibition by JQ1 on intracellular
lipids in HepG2 cells. (A) HepG2 cells were treated with vehicle (Ctrl) or JQ1 (0.4 µM), and after 48
hours they were stained with Oil Red O as described in the Materials and Methods Section to visualize
the intracellular content of neutral lipids. n = 6 different experiments. Scale bar: 50 µm (B) HepG2
cells were treated as in (A), and Oil Red O was extracted with isopropanol. The eluted dye was then
quantified by spectrophotometry to evaluate the amount of neutral lipids. n = 6 different experiments.
(C) Vehicle- and JQ1-treated HepG2 cells were fixed and stained with antibody against Plin2 (red).
DAPI was used as a nuclear counterstain. Scale bar: 25 µm (D) Representative image (left panel) and
quantification of the mean fluorescence intensity (right panel) of filipin staining performed on HepG2
cells treated with vehicle and JQ1 for 48 hours. n = 5 different experiments. Scale bar: 50 µm. Data
represent means ± SD. Statistical analysis was performed by using unpaired Student’s t test. ** p < 0.01;
*** p < 0.001.
2.2. BET Inhibition by JQ1 Modulates the Expression of Proteins and Enzymes Involved in Lipid Metabolism
To understand the cellular mechanisms underlying the reduction of lipid content induced by
BET inhibition, the prospective modulation of proteins belonging to the lipid metabolism machinery
were assessed. The analysis was initially focused on ACC and HMGCR, the rate-limiting enzymes
involved in fatty acid and cholesterol biosynthesis, respectively. Western blot analysis revealed that
JQ1 treatment significantly decreased ACC protein expression if compared to vehicle-treated HepG2
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cells (Figure 2A). However, no changes were observed in the ratio between the phosphorylated fraction
of ACC and its total levels, suggesting that BET inhibition modulated the protein amount of the
enzyme without influencing its activation state by inhibitory phosphorylation. Similar results were
obtained by analyzing HMGCR; in fact, JQ1 administration strongly reduced the protein levels of
the enzyme without affecting its phosphorylation state (Figure 2B). The effect of BET inhibition on
HMGCR expression was further confirmed by confocal analysis, showing an overall decrease of
immunofluorescence intensity in JQ1-treated HepG2 with respect to control cells (Figure 2C).
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(C) Immunofluorescence staining of HMGCR (green) of HepG2 cells treated as in (B). Nuclei were 
counterstained with DAPI. n = 3 different experiments. Scale bar: 50 µm. Data are expressed as means 
± SD. Statistical analysis was carried out by using unpaired Student’s t test. ** p < 0.01; *** p < 0.001. 
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Figure 2. Evaluation of BET inhibition on lipid biosynthesis enzymes. (A) Representative Western
blot (left panel) and densitometric analysis of phosphorylated Acyl Coenzyme A carboxylase (ACC)
(P-ACC, ser79) and total ACC in HepG2 cells treated with vehicle (Ctrl) or JQ1 (0.4 µM) for 48 hours.
n = 6 independent experiments. Tubulin was employed as a housekeeping protein to normalize
protein loading. (B) Representative Western blot (left panel) and densitometric analysis (right panel) of
phosphorylated 3-hydroxy-3-methylglutaryl Coenzyme A reductase (HMGCR) (p-HMGCR, ser872)
and total HMGCR in HepG2 cells treated with vehicle (Ctrl) or JQ1 (0.4 µM) for 48 hours. n = 7
independent experiments. Tubulin served as a housekeeping protein to normalize protein loading.
(C) Immunofluorescence staining of HMGCR (green) of HepG2 cells treated as in (B). Nuclei were
counterstained with DAPI. n = 3 different experiments. Scale bar: 50 µm. Data are expressed as means
± SD. Statistical analysis was carried out by using unpaired Student’s t test. ** p < 0.01; *** p < 0.001.
Lipid homeostasis is guaranteed by a delicate equilibrium between biosynthesis and extracellular
uptake. The latter process is mainly operated by LDLr, which internalizes LDL through
receptor-mediated endocytosis [32]. In addition to LDLr, hepatic cells also express SR-B1, a multiligand
receptor that binds several lipoproteins, including HDL and LDL [33]. Considering their pivotal
role in the physiological regulation of lipid metabolism, the prospective effects mediated by BET
inhibition were also assessed for these two lipoprotein receptors. SR-B1 expression was significantly
repressed by JQ1 treatment, as observed by Western blot and immunofluorescence data (Figure 3A,B).
Similarly, BET inhibition determined a three-fold reduction in LDLr expression levels (Figure 3C).
Immunofluorescence microscopy confirmed this result, being LDLr barely detectable in JQ1-treated
HepG2 cells when compared to vehicle-treated cells (Figure 3D).
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Figure 3. Expression of proteins involved in extracellular lipid uptake and intracellular cholesterol
trafficking following JQ1 (0.4 µM) administration to HepG2 cells for 48 hours. (A) Representative
Western blot (left panel) and densitometric analysis (right panel) of SR-B1. n = 6 independent
experiments. (B) Immunofluorescence analysis of SR-B1 (green). Nuclei were counterstained
with DAPI. n = 3 different experiments. Scale bar: 50 µm. (C) Representative Western blot (left
panel) and densitometric analysis (right panel) of LDLr. n = 5 independent experiments. (D) LDLr
immunofluorescence (green). Nuclei were counterstained with DAPI. n = 3 different experiments.
(E–F) Representative Western blots and densitometric analysis of NPC1 and TMEM97. Tubulin was
chosen as loading control. n = 6 independent experiments. Data represent means ± SD. Statistical
analysis was performed by using unpaired Student’s t test. ** p < 0.01; *** p < 0.001.
Upon binding to lipoprotein receptors, LDL are internalized and transported throughout the
endocytic pathway to lysosomes, where cholesteryl esters can be hydrolyzed by acid lipases [34].
Subsequently, unesterified cholesterol exits the lysosomal compartment, through the activity of NPC1,
and is delivered to the plasma membrane and the endoplasmic reticulum (ER) [35]. Because of its
essential role in intracellular cholesterol trafficking, Niemann-Pick type C1 (NPC1) protein levels were
assessed in this study. BET inhibition by JQ1 strongly enhances NPC1 protein expression in HepG2
cells (Figure 3E). Interestingly, the rise in NPC1 levels was accompanied by a significant reduction of
transmembrane protein 97 (TMEM97) protein content, also known as the sigma-2 receptor (Figure 3F),
which has already been involved in NPC1 regulation [36].
Most proteins involved in lipid metabolism are under the transcriptional control of SREBPs.
Considering the effects of BET inhibition evaluated in this work, the expression of SREBP-1 and
SREBP-2 was estimated. JQ1 treatment induced a significant increase of SREBP-1 precursor (full-length,
FL SREBP-1). However, this effect was not paralleled by a concurrent modification in the nuclear
and transcriptionally active fragment of SREBP-1 (nSREBP-1), as its expression is similar between the
two experimental groups (Figure 4A). Morphological analysis corroborated this evidence, revealing
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a slightly higher fluorescence intensity in the cytosolic compartment in JQ1-treated cells, consistent
with the increase of FL SREBP-1 observed by the Western blot. On the contrary, no differences
were detected in the number and intensity of the stained nuclei, reflecting the lack of significant
alterations in the amount of nSREBP-1 (Figure 4B). Differently from SREBP-1, BET inhibition reduced
the expression of both precursor (FL SREBP-2) and nuclear SREBP-2 (nSREBP-2) (Figure 4C). SREBP-2
immunofluorescence revealed a predominant nuclear staining, and a weak signal in the cytoplasmic
compartment. Notably, JQ1 administration markedly decreased the intensity and the number of nuclei
stained for SREBP-2 (Figure 4D).
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Figure 4. BET inhibition alters sterol regulatory element binding proteins (SREBPs) expression in
HepG2 cells treated with JQ1 (0.4 µM) for 48 hours. (A) Representative Western blot (left panel) and
densitometric analysis (right panel) of SREBP-1. FL SREBP-1 (Full-length SREBP-1); nSREBP-1 (nuclear
SREBP-1). n = 6 independent experiments. Tubulin was employed for control loading. (B) SREBP-1
immunofluorescence staining (green) in HepG2 cells. Nuclei were counterstained with DAPI. n = 3
different experiments. Scale bar: 50 µm. (C) Representative Western blot (left panel) and densitometric
analysis (right panel) of SREBP-2. FL SREBP-2 (Full-length SREBP-2); nSREBP-2 (nuclear SREBP-2).
n = 6 independent experiments. Tubulin was used as a housekeeping protein. (D) Immunofluorescence
analysis of SREBP-2 (green). Nuclei were counterstained with DAPI. n = 3 different experiments. Scale
bar: 50 µm. Data represent means ± SD. Statistical analysis was assessed by using unpaired Student’s t
test. *** p < 0.001.
To further strengthen the effects induced by JQ1 on lipid homeostasis in HepG2 cells,
we recapitulated the most relevant findings in different cell lines. As expected, BET blockade
significantly suppressed the expression of SREBP-2 and of its targets LDLr and HMGCR also in
the neuroblastoma cell line N1E-115 (Figure 5A,B) and in primary culture of human fibroblasts
(Figure 5C,D).
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Figure 5. BET inhibition modulates the expression of SREBP-2, HMGCR and LDLr in different cell
lines. (A–B) Representative Western blot and densitometric analysis of SREBP-2, HMGCR and LDLr
in differentiated N1E-115 treated with JQ1 (0.1 µM) for 48 hours. (C–D) Representative Western blot
and densitometric analysis of SREBP-2, HMGCR and LDLr in primary human fibroblasts treated with
JQ1 (0.4 µM) for 48 hours. n = 3 different experiments. Tubulin and vinculin were used as loading
control. Data represent means ± SD. Statistical analysis was assessed by using unpaired Student’s t test.
* p < 0.05, ** p < 0.01, *** p < 0.001.
Overall, these data indicate that BET inhibition deeply affects the main proteins involved in lipid
biosynthesis, uptake and intracellular transport.
2.3. BET Inhibition Affects Cell Proliferation in a Cholesterol-Dependent Manner
The maintenance of a proper amount of lipids, and in particular of cholesterol, is crucial for
several biological processes, such as cell growth and cell proliferation [4,37]. In addition, it has been
extensively demonstrated that BET inhibition promotes the suppression of cell proliferation in a
number of normal and cancer cell types [19,38,39]. Results collected in this work are in agreement with
previous reports, demonstrating that JQ1 treatment significantly slowed down the proliferation rate of
HepG2 cells starting at 48 hours from the pharmacological treatment (Figure 6A). Remarkably, the cell
growth rate was rescued when JQ1 was co-administered with mevalonate (MVA), the product of the
reaction catalyzed by HMGCR. The involvement of cholesterol biosynthesis in the anti-proliferative
effects mediated by BET inhibition was further supported by the co-administration of cholesterol to
JQ1-treated cells that, similarly to MVA addition, was able to restore cell proliferation. In order to
delve deeper into the effects exerted by BET inhibition on cell proliferation and cholesterol modulation,
we generated a HepG2 lineage with acquired resistance to JQ1 (HepG2-R) by continuously treating
cells with increasing doses of the drug. While JQ1 decreased the number of JQ1-sensitive cells
as previously shown, no effects were induced in HepG2-R upon drug administration (Figure 6B).
Importantly, the restoration of cell proliferation observed in HepG2-R cells was completely abolished
by 25-hydroxycholesterol (25OHC) treatment, a well-known methodological approach to mediate
HMGCR degradation through the activation of a feedback mechanism [40]. Similar results were also
obtained by blocking HMGCR activity with simvastatin, a potent inhibitor of cholesterol biosynthesis
(Figure 6C). Because statins suppress the production of isoprenoid intermediates in the cholesterol
biosynthetic pathway, they can exert a plethora of pleiotropic actions independently from cholesterol
decrease [8]. To confirm a direct involvement, cholesterol was then administered to HepG2-R cells
co-treated with JQ1 and simvastatin. Cholesterol supplementation efficiently prevented the reduction
of cell proliferation induced by simvastatin in HepG2-R cells, thus restoring the acquired resistance to
JQ1 as a function of cell growth (Figure 6D).
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Figure 6. BET inhibition influences cell proliferation through cholesterol metabolism. (A) HepG2 cells
were seeded in 6-well plates (150,000 cells for each well) and were treated with JQ1 (0.4 µM), mevalonate
(MVA, 100 µM) and cholesterol (chol, 50 µM) for 72 hours. Cell counts were conducted over time with
a hemocytometer. (B–C) Cell proliferation was evaluated in JQ1-sensitive (HepG2) and JQ1-resistant
(HepG2-R) cells. JQ1-resistant and -sensitive HepG2 cells were treated with the BET inhibitor for
72 hours, and additional groups of HepG2-R cells were co-stimulated with JQ1+25-hydroxycholesterol
(25OHC, 20 µM) or JQ1+simvastatin (Sim, 1 µM). Other cells were treated with vehicle and served
as control (Ctrl). (D) Cell proliferation was evaluated in JQ1-sensitive (HepG2) and JQ1-resistant
(HepG2-R) cells. JQ1-resistant cells were constantly stimulated with the BET inhibitor. Additional
groups of HepG2-R cells were co-stimulated with JQ1+simvastatin (Sim, 1 µM) or JQ1+Sim+cholesterol
(Chol, 50 µM). n = 4 independent experiments. Data represent means ± SD. Statistical analysis was
assessed by using one-way ANOVA, followed by Dunnett’s post hoc. * p < 0.05; ** p < 0.01; *** p < 0.001.
Overall, these results suggested that the anti-proliferative effects elicited by JQ1 can be mediated
by the suppression of cholesterol metabolism and that the acquisition of resistance to BET inhibition
may be accompanied by adaptive changes in the main proteins controlling cholesterol homeostasis.
Western blot data confirmed this hypothesis, highlighting that both FL SREBP-2 and nSREBP-2 levels
were increased in JQ1-resistant HepG2 cells (Figure 7A). Coherently, the expression of SREBP-2 target
genes HMGCR, SR-B1 and LDLr was properly restored at the level of control cells in HepG2-R cells
(Figure 7B–D). Taken together, these results suggest that the impact of HepG2 proliferation mediated
by BET inhibition is dependent on cholesterol metabolism.
Int. J. Mol. Sci. 2020, 21, 1297 9 of 16Int. J. Mol. Sci. 2020, 21, 1297 9 of 16 
 
 
Figure 7. JQ1 resistance is accompanied by the upregulation of proteins controlling cholesterol 
metabolism. (A–D) Representative Western blots and densitometric analysis of SREBP-2, HMGCR, 
SR-B1and LDLr in JQ1-sensitive cells treated with vehicle (Ctrl) or JQ1 (0.4 µM), and in HepG2-
resistant (JQ1-R) cells constantly stimulated with JQ1 (0.4 µM). Experiments were performed after 48 
hours. n = 4 independent experiments. Tubulin served as loading control. Data represent means ± SD. 
Statistical analysis was assessed by using one-way ANOVA followed by Tukey’s post-hoc. * p < 0.05; 
** p < 0.01; *** p < 0.001. “a” indicates statistical significance versus control group (Ctrl); “b” indicates 
statistical significance compared to JQ1 group. 
3. Discussion 
The homeostatic maintenance of lipid metabolism plays a fundamental role in assuring the 
correct development of cellular functions. As a consequence, alterations in the mechanisms 
controlling lipid balance may be associated to several pathological conditions, ranging from 
cardiovascular diseases and lipidosis to neurodegenerative and neurodevelopmental diseases [13–
15,41]. The discovery of effective lipid-lowering medications, such as statins and fibrates, have 
revolutionized the treatment and the clinical outcomes of different lipid disorders [42]. 
Unfortunately, numerous diseases associated to lipid disturbances do not yet have a resolutive 
therapy. The obstacles in designing efficient pharmacological approaches relies on the fact that 
cellular and molecular mechanisms regulating lipid metabolism are not completely elucidated.  
In this context, it is important to delve deeper into the regulatory mechanisms of lipid 
homeostasis, with the attempt to unravel potential etiopathological factors and novel molecular 
targets that could be useful to set up promising therapies. In the last few years, several reports 
highlighted that epigenetic factors may play crucial roles in the control of lipid homeostasis. For 
instance, it is becoming increasingly clear that histone deacetylases (HDAC) and microRNAs exert a 
crucial modulatory activity in lipid and energy metabolism [43–47]. On the contrary, the involvement 
of BET proteins in the regulation of lipid homeostasis is still elusive. Thus, in this work, we evaluated 
the effects of BET inhibition in the expression of the main proteins controlling lipid metabolism.  
Collectively, our results demonstrated that BET inhibition induced an overall suppression of 
lipid metabolism. In particular, JQ1 administration decreased the intracellular lipid content and 
reduced the expression of biosynthetic enzymes (ACC and HMGCR) as well as of receptors involved 
in lipoprotein uptake (LDLr and SR-B1). BET inhibition also induced a strong downregulation in the 
expression of TMEM97. This conserved integral membrane protein has been identified as an 
important modulator of cholesterol levels and, similarly to other proteins coordinating lipid 
metabolism, is a SREBP-2 target gene [36,48,49]. It is well described that SREBPs isoforms possess 
different roles in lipid biosynthesis. SREBP-1 isoforms are mostly devoted to the regulation of fatty 
acid and triglyceride metabolism, whereas SREBP-2 is relatively selective in activating cholesterol-
Figure 7. JQ1 resistance is accompanied by the upregulation of proteins controlling cholesterol
metabolism. (A–D) Representative Western blots and densitometric analysis of SREBP-2, HMGCR,
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3. Discussion
The homeostatic maintenance of lipid metabolism plays a fundamental role in assuring the correct
development of cellular functio s. As a consequence, alterations in the ch nisms controlli g lipid
balance may be associated to several path logical conditions, ra ging from cardiovascular diseases and
lipid sis to neurodege erative and neur dev lopmental diseases [13–15,41]. The discovery of effective
lipid-lowering medications, such as s atins an fibrates, have revolutionized th treatment and the
clinical outcomes of differ nt lipid disorders [42]. Unfortunately, n merous diseases associated to lipid
disturba ces o not yet hav a resolutive therapy. The obstacles in designing efficient pharmacological
approaches relies on the fact th t cellular and m lecular mechanism regulating lipid metabolism are
not completely elu idated.
In this cont xt, it is important to delve deeper into the regulato y mechanisms of lipid homeostasis,
with the attemp to unravel potential etiopathological factors and novel molecular t rgets that could
be useful to se up promising therapies. In the last few years, several eports highlighted that
epigenetic factors may play crucial roles in the control of lipid homeost is. For instance, it is becoming
increasingly clear that his one deacetyl ses (HDAC) nd microRNAs exe t a crucial modulatory activity
in lipid and energy metaboli m [43–47]. On the contrary, the involvement of BET proteins in he
egulation of lipid homeostasis is still elusive. Thus, in this work, we valuated the effects of BET
inhibition in the expression of the ma n protein controlling ipid metabol sm.
Collectively, our results demonstrated that BET inhibition induced an overall suppression of lipid
metabolism. In particular, JQ1 admi istration decreased t e ntracellular lipid content and reduced the
expression f biosy thetic enzymes (ACC a d HMGCR) as well as of receptors involve in lipoprotein
uptake (LDLr and SR-B1). BET inhibition also induced a strong downregu ation in the expression of
TMEM97. This cons rved integral membrane prote n has been identified as an important modulator of
cholesterol levels and, similarly to other proteins coordinati g lipid metabolism, is a SREBP-2 target
gene [36,48,49]. It is well described that SREBPs isoforms possess different role in lipid biosynthesis.
SREBP-1 isoforms are mostly devot d to the regulation of fatty acid nd triglyceride etabolism,
wh as SREBP-2 is relatively s lective in activating cholester l-relat d g nes [50,51]. Coherently with
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these notions, the JQ1-mediated suppression of HMGCR, LDLr, SR-B1 and TMEM97 was paralleled by
a concurrent decrease of both the full-length and the nuclear active fraction of SREBP-2. Interestingly,
BET inhibition was also responsible for a significant decrease of ACC expression, which, however, was
not adequately accompanied by changes in nSREBP-1 levels. Indeed, the levels of SREBP-1 precursor
were significantly augmented, probably representing a transcriptional attempt to counteract the marked
decrease of the SREBP-2 isoform. Conversely, the expression of the nuclear and transcriptionally active
fragment of SREBP-1 was unaltered upon JQ1 treatment, excluding its involvement in the modulation
of ACC levels. Even though ACC transcription is preferentially controlled by SREBP-1 isoforms [50],
it has been observed that SREBP-2 can equally influence ACC transcription [52], supporting the notion
that the reduction of ACC levels observed in this work may be ascribable to the suppression of SREBP-2
mediated by JQ1. In addition, BET blockade led to a rise in NPC-1 protein levels. Literature data
illustrated that a reduction of TMEM97 increases NPC-1 protein expression by a post-translational
mechanism [36], and suggest that the suppression of TMEM97 could explain the build-up of NPC-1
observed in this study following JQ1 administration. Consistent with JQ1-mediated decrease of LDLr
expression, NPC1 induction may also represent a refined compensatory response to contrast the
prospective decrease of LDL-cholesterol uptake. Furthermore, it cannot be excluded that BET inhibition
directly affects the transcription of NPC1, as well as of other genes involved in the maintenance of
lipid homeostasis.
Subsequently, the prospective contribution of lipid metabolism in the anti-proliferative effects
induced by JQ1 administration was evaluated. It has been extensively reported that BET inhibition
exerts a remarkable reduction in cell proliferation by hindering the transcription of oncogenes such
as c-Myc [53], and by suppressing the activation of pro-survival and growth signalling kinases like
Akt [26]. In this study, we highlight for the first time a novel mechanism by which BET inhibition
modulates cell proliferation in a cholesterol-dependent manner. Indeed, the administration of both
MVA and cholesterol to culture medium efficiently abolished the delay in cell proliferation induced
by JQ1. Consistently, the generation of HepG2-R cells further corroborated this evidence, as the
acquisition of resistance to JQ1 is associated to the compensatory increase in the expression of proteins
belonging to cholesterol metabolism, and to the restoration of cell proliferation rate.
Overall, these data suggest that BET inhibition reduces lipid content by hampering SREBP-2
expression and processing, which result in a reduced expression of target genes involved in lipid
biosynthesis, uptake and intracellular trafficking.
Despite the fact that more efforts should be done in order to better clarify the specific contribution
of each BET protein in the regulation of lipid metabolism, this work provides the proof of principle that
epigenetic pathways, influenced by BET protein activity, represent novel physiological mechanisms to
control lipid homeostasis. These findings may also set the basis for designing innovative therapeutic
approaches aimed at ameliorating the functional outcomes of several disorders characterized by
lipid unbalances.
4. Materials and Methods
4.1. Cell Cultures and Generation of HepG2 Resistant to JQ1
N1E-115 neuroblastoma cells were cultured at 5% CO2 in DMEM medium at high glucose,
containing 10% (v/v) foetal calf serum, L -glutamine (2 mM), and added with penicillin/streptomycin
solution. Cells were then seeded at 50% confluency and were induced to differentiate for four hours by
adding 2% dimethyl sulfoxide. Differentiated N1E-115 cells were treated with JQ1 (0.1 µM) or vehicle
(DMSO, dilution 1:1000 in cell culture media) for 48 hours.
Human foetal foreskin fibroblasts (HFFF2) were grown at 5% CO2 in DMEM (high glucose)
additioned with 10% foetal calf serum, L -glutamine (2 mM), and penicillin/streptomycin solution.
HFFF2 (60% confluency) were then treated with 0.4 µM JQ1 for 48 hours. Cells treated with vehicle
(DMSO, dilution 1:1000 in cell culture media) served as control.
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HepG2 cells were routinely cultured at 5% CO2 in DMEM medium at high glucose, containing 10%
(v/v) foetal calf serum, L -glutamine (2 mM), and added with penicillin/streptomycin solution. Cells
were passaged every 3 days and medium changed every 2–3 days. All the experiments were performed
with cell confluency of 60%–70%. DMSO stock of 4 mM JQ1 was diluted 1:1000 in cell culture media
to obtain the final concentration of 0.4 µM JQ1. Experiments were then performed 48 hours after
JQ1 stimulation. Cells treated with vehicle (DMSO, dilution 1:1000 in cell culture media) served as
control. The generation of HepG2 cells resistant to JQ1 was carried out by slightly modifying the
protocol provided by Gobbi and colleagues [54]. HepG2 resistant cells were selected by continuously
applying increasing doses of JQ1, starting from 50 nM and enhancing the drug concentration every
1–2 weeks for 2 months of total treatment. Surviving JQ1-resistant cells were then maintained at 0.4 µM
JQ1 throughout. For cell proliferation experiments, chemicals were purchased from Sigma-Aldrich
and used at the following concentrations: JQ1 (0.4 µM), mevalonate (100 µM), cholesterol (50 µM),
simvastatin (1 µM), 25-hydroxycholesterol (20 µM).
4.2. Oil Red O Staining and Quantification
For the evaluation of lipid content, HepG2 cells were seeded in 12-well plates. Briefly, after
48 hours of JQ1 treatment, cells were fixed in paraformaldehyde (4% solution) for 10 minutes and
gently rinsed twice with PBS. Sixty per cent isopropanol was added to fixed cells for 5 minutes,
and then washed 2 times with distilled water. Cells were stained with 1 mL of the Oil Red O solution
(Sigma-Aldrich, Milan, Italy) for 15 minutes at room temperature with continuous gentle shaking.
Subsequently, wells were then rinsed 3 times with distilled water, until no excess stain was seen.
Stained cells were visualized in brightfield using an Olympus BX 51 microscope (Olympus Italia,
Segrate, Italy), equipped with a Leica DFC 420 camera (Leica Microsystems, Milan, Italy). Electronic
images were captured using a Leica Application Suite version 3.5.0 system (Leica Microsystems, Milan,
Italy). For relative Oil Red O accumulation by spectrophotometry, after incubation with Oil Red O
solution, stained cells were washed 3 times with distilled water, and the dye was eluted by the addition
of 1 mL isopropanol for 15 minutes, with gentle shaking. A total of 100 µL of the eluted dye was
removed from each sample and were transferred to a clean 96-well plate for reading the absorbance at
540 nm.
4.3. Filipin Staining
Filipin staining was performed as previously described [55]. Filipin staining was performed using
Filipin complex (Sigma-Aldrich, catalog #F9765). Filipin stock solution (10mg/mL in PBS) was freshly
prepared before the use. Cells were fixed in paraformaldehyde (4% solution) for 10 minutes and rinsed
3 times with PBS. Cells were stained with 1mL Filipin working solution (0.05 mg/mL in PBS) for 2
hours at room temperature, in the dark. Next, wells were rinsed 3 times with PBS to remove excess dye.
Finally, cells were viewed in PBS through a fluorescence microscope using a UV filter set (340–380 nm
excitation). Images were acquired at 20× magnification using an Axio Imager Z2 (Carl Zeiss, Jena,
Germany) equipped with a charge-coupled device (CCD) camera controlled by the ISIS software
(MetaSystems, Milano, Italy). Filipin quantification was calculated as the mean fluorescence intensity
per cell area by using ImageJ Software for Windows.
4.4. Lysate Preparation and Western Blot Analysis
HepG2 lysate was performed as already reported [56]. Forty-eight hours after treatment, cells
were lysed in 80 µL lysis buffer (0.25 M Tris pH 6.8, 10% SDS, phosphatase and protease inhibitor
cocktails) by sonication (duty cycle 20%, output 3). Samples were then centrifuged at 10,000g for 10
min to remove cell debris. Protein concentration was assessed by the method of Lowry. Subsequently,
Laemmli buffer was added to HepG2 lysates, and samples were boiled for 3 min before loading to
the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) for subsequent western
blot analysis.
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Western blot experiments were performed by slightly modifying the previously described
protocol [8]. Briefly, proteins (30 µg) from HepG2 lysates were resolved on SDS-PAGE at 40 mA
(constant current) for 60 min. Subsequently, proteins were transferred onto nitrocellulose membrane
by using Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, Milan, Italy). The nitrocellulose
membrane was incubated at room temperature with 5% fat-free milk in Tris-buffered saline (0.138 M
NaCl, 0.027 M KCl, 0.025 M Tris-HCl, and 0.05% Tween-20, pH 6.8), and probed at 4 ◦C overnight
with the following primary antibodies: phopsho-HMGCR (Merck Millipore, #09-356, dilution 1:1000),
HMGCR (Abcam, ab242315, dilution 1:1000), phospho-ACC (Sigma-Aldrich, SAB4503851, dilution
1:500), ACC (Sigma-Aldrich, SAB4501396, dilution 1:500), SR-B1 (Abcam, Cambridge, UK, ab52629,
dilution 1:2000), LDLr (Abcam, ab30532, dilution 1:1000), NPC1 (Novus Biologicals, NB400-148, dilution
1:1000), TMEM97 (Novus Biologicals, Centennial, CO, USA, NBP1-30436, dilution 1:1000), SREBP-2
(Abcam, ab30682, dilution 1:1000), SREBP-1 (Santa Cruz Biotechnology, sc-8984, dilution 1:1000),
alpha-Tubulin (Sigma-Aldrich, T6199, dilution 1:10000), vinculin (Sigma-Aldrich, V9131, dilution
1:20.000). Subsequently, membranes were probed for 1 hour with horseradish peroxidase conjugated
secondary IgG antibodies (Bio-Rad Laboratories, Milan, Italy). Protein-antibody immunocomplexes
onto nitrocellulose were visualized by using clarity ECL Western blotting (Bio-Rad Laboratories, Milan,
Italy, #1705061), and chemiluminescence acquisition was carried out through ChemiDoc MP system
(Bio-Rad Laboratories). Western blotting images were analyzed by ImageJ (National Institutes of
Health, Bethesda, MD, USA) software for Windows. All samples were normalized for protein loading
with alpha-Tubulin (chosen as a housekeeping protein). Recorded values were derived from the ratio
between arbitrary units obtained from the protein band and the respective housekeeping protein.
4.5. Immunofluorescence Staining
Immunofluorescence of HepG2 cells was performed by following the previously described
protocol [17]. Cells were fixed in paraformaldehyde (4% in PBS) and incubated overnight with
appropriate antibodies: HMGCR (Abcam, ab242315, dilution 1:100), SREBP-2 (Abcam, ab30682, dilution
1:100), SREBP-1 (Santa Cruz Biotechnology, Dallas, TX, USA, sc-8984, dilution 1:100), SR-B1 (Abcam,
ab52629, dilution 1:100), LDLr (Santa Cruz Biotechnology, sc-11824, dilution 1:200), anti-Perilipin-2
(anti-Plin2) antibody (R&D Systems, #MAB76341, dilution 1:100). After incubation with primary
antibodies, fixed cells were probed for 1 hour at room temperature with donkey anti-goat secondary
antibody Alexa Fluor 488 (ThermoFisher Scientific, Milan, Italy, A-11055), goat anti-rabbit secondary
antibody Alexa Fluor 555 (ThermoFisher Scientific, A27039) and goat anti-rabbit secondary antibody
Alexa Fluor 488 (ThermoFisher Scientific, A-11008). Coverslips were mounted with Vectashield
Antifade mounting medium with DAPI (Vector, H-1200) to visualize nuclear staining. The samples
were examined at confocal microscopy (TCS SP8; Leica, Wetzlar, Germany). Images were captured
using Leica TCS SP8 equipped with a 40 × 1.40–0.60 NA HCX Plan Apo oil BL objective at RT and
Leica LAS X Software.
4.6. Statistical Analysis
All the results are expressed as mean ± standard deviation (SD). Normal distribution of the data
was assessed by applying the Shapiro–Wilk test. Unpaired Student’s t test was performed to compare
means between two experimental groups. When comparing three or more experimental groups,
one-way analysis of variance (ANOVA) was carried out, followed by Tukey’s or Dunnett’s post hoc.
p < 0.05 was considered to indicate a statistically significant difference. Statistical analysis and graph
editing were performed using GRAPHPAD INSTAT3 (GraphPad, La Jolla, CA, USA) for Windows.
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Abbreviations
ACC Acyl Coenzyme A carboxylase
BET Bromodomain and extra-terminal domain
HDAC histone deacetylases
HDL high density lipoprotein
HMGCR 3-hydroxy-3-methylglutaryl Coenzyme A reductase
LDL low density lipoprotein
LDLr low density lipoprotein receptor
NPC1 Niemann-Pick type C1
ROS reactive oxygen species
SR-B1 scavenger receptor class B type 1
SREBPs sterol regulatory element binding proteins
TMEM97 transmembrane protein 97
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